BRANMOOR
THURSDAY · 14 MAY 2026

Lincomycin Hydrochloride

Injection · trading as Lincomycin

To Be Discontinued Active (discontinuing) — Day 49 FDA record updated

Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.

FDA shortage record

Substance
Lincomycin Hydrochloride
Brand name
Lincomycin
Manufacturer
XGen Pharmaceuticals DJB, Inc.
Dosage form
Injection
Presentation
Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)
Route(s)
INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL
Therapeutic category
Anti-Infective
Package NDC
39822-0350-2
Initially posted
03/26/2026
Days on shortage list
49
Discontinued
03/26/2026
Current FDA status
To Be Discontinued
Shortage entries (current dataset)
2 records for Lincomycin Hydrochloride

Why this shortage matters

Anti-infective drugs — antibiotics, antivirals, and antifungals — treat bacterial, viral, and fungal infections. A shortage can delay care for serious hospital-acquired or opportunistic infections, where drug choice and timing directly affect patient outcomes.

FDA therapeutic class: Anti-Infective

Reason and context

A business decision was made to discontinue manufacture of the drug.

Manufacturer contact

Per the FDA record, the manufacturer's contact for supply inquiries is 866-390-4411.

If you're affected by this shortage

  • Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
  • Ask your pharmacy to check supply across multiple wholesalers and other branches.
  • Check current pharmacy pricing and availability via GoodRx (affiliate link).
  • Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.

Sources

Important

This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.